191 related articles for article (PubMed ID: 37127491)
1. Challenges in scaling up AAV-based gene therapy manufacturing.
Jiang Z; Dalby PA
Trends Biotechnol; 2023 Oct; 41(10):1268-1281. PubMed ID: 37127491
[TBL] [Abstract][Full Text] [Related]
2. Quality Control Testing, Characterization and Critical Quality Attributes of Adeno-Associated Virus Vectors Used for Human Gene Therapy.
Wright JF
Biotechnol J; 2021 Jan; 16(1):e2000022. PubMed ID: 33146911
[TBL] [Abstract][Full Text] [Related]
3. Manufacturing and characterizing AAV-based vectors for use in clinical studies.
Wright JF
Gene Ther; 2008 Jun; 15(11):840-8. PubMed ID: 18418418
[TBL] [Abstract][Full Text] [Related]
4. Assessment of quality attributes for adeno-associated viral vectors.
Tustian AD; Bak H
Biotechnol Bioeng; 2021 Nov; 118(11):4186-4203. PubMed ID: 34309017
[TBL] [Abstract][Full Text] [Related]
5. Development and Delivery of a Hands-On Short Course in Adeno-Associated Virus Manufacturing to Support Growing Workforce Needs in Gene Therapy.
Overton L; Boi C; Shastry S; Smith-Moore C; Balchunas J; Sambandan D; Gilleskie G
Hum Gene Ther; 2023 Apr; 34(7-8):259-272. PubMed ID: 36860188
[TBL] [Abstract][Full Text] [Related]
6. Manufacturing Challenges and Rational Formulation Development for AAV Viral Vectors.
Srivastava A; Mallela KMG; Deorkar N; Brophy G
J Pharm Sci; 2021 Jul; 110(7):2609-2624. PubMed ID: 33812887
[TBL] [Abstract][Full Text] [Related]
7. Moving from the bench towards a large scale, industrial platform process for adeno-associated viral vector purification.
Adams B; Bak H; Tustian AD
Biotechnol Bioeng; 2020 Oct; 117(10):3199-3211. PubMed ID: 32573761
[TBL] [Abstract][Full Text] [Related]
8. Adeno-associated virus vector as a platform for gene therapy delivery.
Wang D; Tai PWL; Gao G
Nat Rev Drug Discov; 2019 May; 18(5):358-378. PubMed ID: 30710128
[TBL] [Abstract][Full Text] [Related]
9. Cellular pathways of recombinant adeno-associated virus production for gene therapy.
Sha S; Maloney AJ; Katsikis G; Nguyen TNT; Neufeld C; Wolfrum J; Barone PW; Springs SL; Manalis SR; Sinskey AJ; Braatz RD
Biotechnol Adv; 2021; 49():107764. PubMed ID: 33957276
[TBL] [Abstract][Full Text] [Related]
10. Optimization of the quality by design approach for gene therapy products: A case study for adeno-associated viral vectors.
Tanaka T; Hanaoka H; Sakurai S
Eur J Pharm Biopharm; 2020 Oct; 155():88-102. PubMed ID: 32784043
[TBL] [Abstract][Full Text] [Related]
11. Drug product Formulation and Fill/Finish Manufacturing Process Considerations for AAV-Based Genomic Medicines.
Som M; Gikanga B; Kanapuram V; Yadav S
J Pharm Sci; 2024 Jul; 113(7):1711-1725. PubMed ID: 38570073
[TBL] [Abstract][Full Text] [Related]
12. The state of the art of adeno-associated virus-based vectors in gene therapy.
Coura Rdos S; Nardi NB
Virol J; 2007 Oct; 4():99. PubMed ID: 17939872
[TBL] [Abstract][Full Text] [Related]
13. Basic biology of adeno-associated virus (AAV) vectors used in gene therapy.
Balakrishnan B; Jayandharan GR
Curr Gene Ther; 2014; 14(2):86-100. PubMed ID: 24588706
[TBL] [Abstract][Full Text] [Related]
14. Leveraging rAAV bioprocess understanding and next generation bioanalytics development.
Escandell JM; Pais DA; Carvalho SB; Vincent K; Gomes-Alves P; Alves PM
Curr Opin Biotechnol; 2022 Apr; 74():271-277. PubMed ID: 35007989
[TBL] [Abstract][Full Text] [Related]
15. Adeno-associated virus vectorology, manufacturing, and clinical applications.
Grieger JC; Samulski RJ
Methods Enzymol; 2012; 507():229-54. PubMed ID: 22365777
[TBL] [Abstract][Full Text] [Related]
16. Treatment to cure: Advancing AAV gene therapy manufacture.
Young P
Drug Discov Today; 2023 Jul; 28(7):103610. PubMed ID: 37169134
[TBL] [Abstract][Full Text] [Related]
17. Immune responses to AAV vectors: overcoming barriers to successful gene therapy.
Mingozzi F; High KA
Blood; 2013 Jul; 122(1):23-36. PubMed ID: 23596044
[TBL] [Abstract][Full Text] [Related]
18. Adeno-associated virus vectors for gene therapy: more pros than cons?
Monahan PE; Samulski RJ
Mol Med Today; 2000 Nov; 6(11):433-40. PubMed ID: 11074369
[TBL] [Abstract][Full Text] [Related]
19. Manufacturing of recombinant adeno-associated viruses using mammalian expression platforms.
Robert MA; Chahal PS; Audy A; Kamen A; Gilbert R; Gaillet B
Biotechnol J; 2017 Mar; 12(3):. PubMed ID: 28177193
[TBL] [Abstract][Full Text] [Related]
20. Recombinant Adeno-Associated Virus Quality Control for Non-Clinical and Clinical Vectors: How an Unregulated Commercial Sector Can Compromise Development of New Gene Therapies.
Kotin RM; Wright JF
Hum Gene Ther; 2019 Dec; 30(12):1447-1448. PubMed ID: 31860397
[No Abstract] [Full Text] [Related]
[Next] [New Search]
